This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
9 Aug 2011

European Commission Approves Boehringer's Oral Anticoagulant Pradaxa

Regulators in Europe have given approval to Boehringer Ingelheim's oral anticoagulant Pradaxa for stroke prevention.

The European Commission has approved Boehringer Ingelheim's oral anticoagulant Pradaxa as a preventive measure for stroke in patients suffering from atrial fibrillation.

 

Pradaxa has been specifically approved for the prevention of strokes in patients with atrial fibrillation in doses of 150mg BID, while a 110mg BID dose has been approved for use in patients aged 80 years or older.

 

Pradaxa has already been approved for the prevention of strokes in the US, Canada, Japan and Australia.

 

The drug had previously been cleared to prevent blood clots after hip and knee surgery. The latest approval was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use earlier this year.

Related News